<DOC>
	<DOCNO>NCT01849757</DOCNO>
	<brief_summary>The purpose study determine prim fluid safe use prim heart-lung machine use cardiopulmonary bypass patient undergoing cardiac surgery . The fluid compare albumin voluven . A control group receive crystalloid .</brief_summary>
	<brief_title>Comparison Priming Constituents Patients Undergoing CPB Assisted Cardiac Surgery : HES 130/0.4 Albumin 5 %</brief_title>
	<detailed_description>Project title : Comparison prim constituent patient undergo CPB assist cardiac surgery : 6 % HES 130/0.4 Albumen 5 % Principal investigator : Jo-Anne Marcoux M . Sc. , CPC , CCP Department : Clinical Perfusion Sub-investigators : Victor Uppal B . Sc. , CPC , CCP Taras Mycyk MD , FRCSC , Research conduct : cardiac operating room Royal University Hospital , affiliate hospital Hypothesis It hypothesize use artificial colloid ( 6 % hydroxyethyl starch 130/0.4 ) ( HES ) prim constituent disruptive coagulation renal system compare use human derive albumen . It hypothesize patient undergo cardiopulmonary bypass ( CPB ) HES 130/0.4 prim constituent demonstrate decrease creatinine clearance increase post-operative bleeding transfusion requirement . Academic validity Permissive hemodilution result crystalloids colloid substitute blood priming fluid cardiopulmonary bypass circuit . While obvious benefit decrease autologous blood exposure patient undergo CPB , determine physiological substitution conclusively resolve . Historically , available HES great molecular weight product currently use associate detrimental adverse event compare saline fluid replacement therapy ( 5.3 % vs. 2.8 % , p &lt; 0.001 ) . ( 1 ) When albumin compare HES 450/0.7 HES 200/0.05 fluid management adult CPB surgery , ( 18 trial 970 patient ) HES increase transfusion red blood cell 28.4 % ( p = 0.027 ) , increased transfusion fresh-frozen plasma 30.6 % ( p = 0.008 ) increase transfusion platelets 29.8 % ( p = 0.027 ) . HES 130/0.4 could compare albumen study insufficient data collect . However , significant difference find compare transfusion requirement HES 450/0.7 , HES 200/0.05 HES 130/0.4 . ( 2 ) Viscoelastic device analysis conclude administration HES 130/0.4 patient healthy volunteer result weak small clot . ( 3 ) Short-time infusion HES 200/0.5 HES 130/0.4 cardiac surgery produce temporary impairment fibrin formation clot strength human albumin effect . ( 4 ) In regard association HES renal failure , one hand use HES 130/0.4 prim fluid use child undergo CPB result negative effect renal function safe use pediatric population . ( 5 ) On hand , use resuscitative measure 7000 randomly assign patient admit intensive care , though difference 90 day mortality group assign HES 130/0.4 group assign saline , patient assign HES 130/0.4 require renal replacement therapy . ( 1 ) When use immediately CPB double-blind clinical trial compare 4 % gelatin , Ringer 's solution HES 130/0.4 , find significantly low mean creatinine level find HES 130/0.4 group compare two group . ( 6 ) Our research direct toward determine conclusively HES 130/0.4 similar risk profile HES 450/0.7 HES 200/0.05 use prim constituent CPB circuit . Additionally determine albumin/crystalloid prime superior HES 130/0.4/crystalloid prime . A fully crystalloid prime control group include control comparison . Research design/Methods The randomized , control trial . Three group subject study : 1 . Control group : Crystalloid prime - 2 L crystalloid prime , - 2.5 mL/kg Mannitol 20 % , - 1 ampoule NaHCO-3 ( 50 mL ) , - 10,000 iu heparin 2 . Voluven ( light ? ) : - HES 130/0.4 prime 500 mL - balance crystalloid - 2.5 mL/kg Mannitol 20 % , - 1 ampoule NaHCO-3 ( 50 mL ) , - 10,000 iu heparin 3 . Albumin : - Human albumin 500 mL 5 % - balance crystalloid - 2.5 mL/kg Mannitol 20 % , - 1 ampoule NaHCO-3 ( 50 mL ) , - 10,000 iu heparin Statistical Analysis We would like 7000 subject include research project . Study population outcomes patient undergo CPB assist cardiac surgery extremely vary . An extremely large population size necessary answer research question propose prim difference question result subtle outcome difference . All patient undergo CPB assist cardiac surgery . Blood sample draw routine interval subject . Blood sample upon enter operating room , completion surgery , 24 hour post-operatively . The amount blood drawn beyond usual test analysis relate care affected patient undergo CPB assist cardiac surgery . ) Inclusion criterion : - great 50 year age - afflict co-morbidities associated cardiac disease ( increase cholesterol , hypertension , smoking , diabetes , previous myocardial infarction decrease ejection fraction ) Exclusion criterion : - emergency - renal failure - dialysis dependent The cardiac center involve date : RUH Saskatoon The goal recruitment cardiac center western Canada . Primary end-points : postoperative bleeding transfusion autologous unit red blood cell , frozen plasma platelet . Secondary end-points : Post-operative renal function parameter creatinine Data collection ongoing . Interim analysis complete half patient recruit final statistical analysis conduct data capture complete . Potential Significance/Justification CPB assist cardiac surgical outcome improve tremendously since first procedure do 1953 . Outcome improvement always come small change evidence base . This research project mean determine safest prime procedure , occur roughly 2,000,000/year throughout world . In regard cost study solution question , $ 4.10 difference cost 500 mL HES 130/0.4 prime 500 mL 5 % Albumin HES 130/0.4 expensive .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>patient undergo cardiopulmonary bypass assist cardiac surgery emergencies patient renal failure dialysis</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Cardiopulmonary bypass</keyword>
	<keyword>prime</keyword>
	<keyword>crystalloid</keyword>
	<keyword>albumin</keyword>
	<keyword>HES 130/0.4</keyword>
</DOC>